Novartis reported stronger-than-expected results in the second quarter, primarily driven by robust sales of new cancer treatments that compensated for reduced revenue from the former top-selling drug Entresto. CEO Vas Narasimhan discussed the company’s approach to managing the impact of patent expirations experienced in the first half of the year. He highlighted the focus on innovation and pipeline investments as key strategies to sustain growth through upcoming product launches.
Narasimhan also addressed the challenges of balancing research and development costs with shareholder returns amid a competitive pharmaceutical landscape. He pointed to promising developments in oncology and cardiovascular therapies as the main drivers for future expansion. The CEO expressed confidence in the company’s ability to create long-term value despite pressures from generic drug competition. This overview provides investors with insight into Novartis’s financial health and strategic direction in the evolving healthcare market.